PubMed Health⌕ Search

PubMed · 15316952

Marginalized transition models for longitudinal binary data with ignorable and non-ignorable drop-out.

Abstract

We extend the marginalized transition model of Heagerty to accommodate non-ignorable monotone drop-out. Using a selection model, weakly identified drop-out parameters are held constant and their effects evaluated through sensitivity analysis. For data missing at random (MAR), efficiency of inverse probability of censoring weighted generalized estimating equations (IPCW-GEE) is as low as 40 per cent compared to a likelihood-based marginalized transition model (MTM) with comparable modelling burden. MTM and IPCW-GEE regression parameters both display misspecification bias for MAR and non-ignorable missing data, and both reduce bias noticeably by improving model fit.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Brenda F Kurland, Patrick J Heagerty. 2004-09-15. Marginalized transition models for longitudinal binary data with ignorable and non-ignorable drop-out.. https://doi.org/10.1002/sim.1850

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Differential pharmacology of atypical antipsychotics: clinical implications.

PURPOSE: Pharmacology of atypical antipsychotics and the clinical implications are reviewed. SUMMARY: Psychiatric disorders, such as schizophrenia and bipolar disorder, are often associated with poor outcomes. Atypical antipsychotics have become the standard of care for these disorders, and multiple agents have demonstrated efficacy for both acute and maintenance therapy. As a result of their differential pharmacologic properties, atypical antipsychotics have diverse clinical profiles, resulting in different liabilities for specific adverse events. These effects can, in turn, have an adverse impact on patient functionality, adherence to therapy, and overall health. CONCLUSION: Atypical antipsychotics have distinct pharmacological profiles which result in clinically meaningful differences in adverse effects. Clinicians should have a wide choice of agents available with which to optimize outcomes in the majority of patients with psychiatric disorders.

Antipsychotic Agents↗